Phase II Study of Paclitaxel for Ovarian Stromal Tumors as First-Line or Second-Line Therapy
OBJECTIVES:
- Determine the clinical response to paclitaxel in patients with ovarian stromal cancer.
- Determine toxicity of this drug in these patients.
- Determine the value of inhibin for predicting response in these patients when treated
with this regimen.
OUTLINE: This is a multicenter study. Patients are stratified according to prior treatment
(yes vs no).
Patients receive paclitaxel IV over 3 hours on day 1. Treatment continues every 21 days in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 2 years, then every 6 months for three years, and
then annually thereafter.
PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.
Interventional
Masking: Open Label, Primary Purpose: Treatment
Frequency of complete clinical response
No
Linda Van Le, MD
Study Chair
UNC Lineberger Comprehensive Cancer Center
Unspecified
CDR0000068149
NCT00006227
November 2000
Name | Location |
---|---|
CCOP - Christiana Care Health Services | Wilmington, Delaware 19899 |
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus | New Britain, Connecticut 06050 |
Bronson Methodist Hospital | Kalamazoo, Michigan 49007 |
West Michigan Cancer Center | Kalamazoo, Michigan 49007-3731 |
Borgess Medical Center | Kalamazooaa, Michigan 49001 |
Aultman Cancer Center at Aultman Hospital | Canton, Ohio 44710-1799 |
MetroHealth Cancer Care Center at MetroHealth Medical Center | Cleveland, Ohio 44109 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Holden Comprehensive Cancer Center at University of Iowa | Iowa City, Iowa 52242-1002 |
Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio 44195 |
Blumenthal Cancer Center at Carolinas Medical Center | Charlotte, North Carolina 28232-2861 |
SUNY Downstate Medical Center | Brooklyn, New York 11203 |
Riverside Methodist Hospital Cancer Care | Columbus, Ohio 43214 |
Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center | Savannah, Georgia 31403-3089 |
Lucille P. Markey Cancer Center at University of Kentucky | Lexington, Kentucky 40536-0093 |
University of Mississippi Cancer Clinic | Jackson, Mississippi 39216-4505 |
Oklahoma University Cancer Institute | Oklahoma City, Oklahoma 73104 |
University of Virginia Cancer Center | Charlottesville, Virginia 22908 |
Todd Cancer Institute at Long Beach Memorial Medical Center | Long Beach, California 90801 |
Cleveland Clinic Cancer Center at Fairview Hospital | Cleveland, Ohio 44111 |
Hillcrest Cancer Center at Hillcrest Hospital | Mayfield Heights, Ohio 44124 |
Cancer Care Associates - Saint Francis Campus | Tulsa, Oklahoma 74136-1929 |
Rosenfeld Cancer Center at Abington Memorial Hospital | Abington, Pennsylvania 19001 |
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest | Allentown, Pennsylvania 18105 |
Cancer Institute of New Jersey at Cooper - Voorhees | Voorhees, New Jersey 08043 |
Palo Alto Medical Foundation | Palo Alto, California 94301 |
UAB Comprehensive Cancer Center | Birmingham, Alabama 35294 |
Tunnell Cancer Center at Beebe Medical Center | Lewes, Delaware 19958 |
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center | Columbus, Ohio 43210-1240 |
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center | Hershey, Pennsylvania 17033-0850 |
Fox Chase Cancer Center CCOP Research Base | Philadelphia, Pennsylvania 19140 |
Union Hospital of Cecil County | Elkton MD, Maryland 21921 |
Duke Cancer Institute | Durham, North Carolina 27710 |
Gynecologic Oncology | Hinsdale, Illinois 60521 |
Louisville Oncology at Norton Cancer Institute - Louisville | Louisville, Kentucky 40202 |
Women's Cancer Center - La Canada | Las Vegas, Nevada 89169 |
South Carolina Oncology Associates, PA | Columbia, South Carolina 29210 |